Topics:
Sarcoma • Medical Oncology
Would you offer imatinib to a patient with a high risk GIST (> 10 cm, low Ki-67, s/p complete resection) who initially declined adjuvant therapy, but is now interested 14 months post surgery?
Is there any data to suggest delayed initiation of adjuvant treatment would be beneficial? Or would close surveillance be reasonable? Patient is asymptomatic and recent surveillance imaging was negative.
Answer from: Medical Oncologist at Academic Institution
In general adjuvant treatment is usually initiated within 3 months of diagnosis. It would be helpful to know more detail about this GIST. For example, where was it located, what was the mitotic count and was any mutational analysis performed.
I am not aware of any data which speci...
Sign in or Register to read more